$0.70
+0.00 (+0.34%)
Open$0.66
Previous Close$0.70
Day High$0.70
Day Low$0.66
52W High$7.00
52W Low$0.53
Volume—
Avg Volume59.1K
Market Cap5.20M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,371.5% upside
Current
$0.70
$0.70
Target
$10.33
$10.33
$6.34
$10.33 avg
$12.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 2.03M | 2.27M |
| Net Income | 217.1K | 264.7K | 291.2K |
| Profit Margin | 10.1% | 13.0% | 12.9% |
| EBITDA | 334.0K | 340.0K | 365.4K |
| Free Cash Flow | 225.5K | 170.6K | 157.9K |
| Rev Growth | +23.7% | +5.3% | -4.1% |
| Debt/Equity | 1.01 | 0.93 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |